Armata Pharmaceuticals, Inc. (ARMP)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Grant and award revenue | 2,169 | 491 | 2,973 | - |
| Research and development | 6,394 | 5,429 | 9,485 | 8,475 |
| General and administrative | 2,619 | 3,253 | 3,244 | 3,439 |
| Total operating expenses | 9,013 | 8,682 | 12,729 | 11,914 |
| Operating loss | -6,844 | -8,191 | -9,756 | -11,914 |
| Investment income, interest | - | - | - | 221 |
| Interest expense | - | - | - | 2,718 |
| Interest income | 108 | 59 | 294 | - |
| Interest expense | 3,808 | 3,602 | 2,923 | - |
| Change in fair value of the convertible loan | -5,751 | 5,203 | 6,904 | 23,397 |
| Total other income (expense), net | -9,451 | 1,660 | 4,275 | 20,900 |
| Net income (loss) | -16,295 | -6,531 | -5,481 | 8,986 |
| Earnings per share, basic | -0.45 | -0.18 | -0.15 | 0.25 |
| Earnings per share, diluted | -0.45 | -0.2 | -0.15 | -0.25 |
| Weighted average number of shares outstanding, basic | 36,193,479 | 36,184,802 | 36,180,124 | 36,154,521 |
| Weighted average number of shares outstanding, diluted | 36,193,479 | 59,478,662 | 36,180,124 | 58,246,626 |